Biotech takes a Christmas beating after safety fears force researchers to halt all hep B studies
There’s no place to run, no place to hide when a critical failure occurs. That includes Christmas break. Spring Bank Pharmaceuticals $SBPH took a beating Thursday morning after announcing that investigators had spotted safety problems with their Phase IIb study for their hepatitis B therapy, inarigivir soproxil 400mg. They’re stopping